Biostage (OTCMKTS:BSTG) is scheduled to post its quarterly earnings results before the market opens on Tuesday, November 12th. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Biostage (OTCMKTS:BSTG) last announced its earnings results on Tuesday, August 13th. The company reported ($0.37) EPS for the quarter.

Shares of BSTG opened at $2.50 on Friday. Biostage has a one year low of $0.75 and a one year high of $3.30. The company’s fifty day moving average price is $2.42 and its 200 day moving average price is $2.41. The company has a current ratio of 2.28, a quick ratio of 2.28 and a debt-to-equity ratio of 0.01.

Separately, ValuEngine upgraded shares of Biostage from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd.

About Biostage

Biostage, Inc, a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities.

Further Reading: Basic Economics

Earnings History for Biostage (OTCMKTS:BSTG)

Receive News & Ratings for Biostage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage and related companies with MarketBeat.com's FREE daily email newsletter.